Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Scholar Rock Holding (SRRK).
Scholar Rock Holding Corporation revealed promising results from its Phase 1 DRAGON trial of SRK-181 with pembrolizumab for advanced solid tumors at the ASCO 2024 Annual Meeting, showing the treatment’s good tolerance and encouraging responses in various cancers. Key findings included a correlation between CD8+ T-cell presence and improved response rates in renal cell carcinoma. The company plans to discuss the details in a conference call and suggests that CD8+ status and regulatory T-cell levels may be biomarkers for identifying patients most likely to benefit from the treatment.
Learn more about SRRK stock on TipRanks’ Stock Analysis page.
